<DOC>
	<DOCNO>NCT00001054</DOCNO>
	<brief_summary>To obtain tolerance , safety , pharmacokinetic data oral valacyclovir hydrochloride ( 256U87 ) HIV-1 infected child herpes simplex virus infection ( cold sore ) and/or varicella / zoster virus infection ( chicken pox / shingle ) . Varicella zoster common problem HIV-infected child . It believe chronic oral therapy acyclovir may result subtherapeutic concentration acyclovir , result resistance drug . Valacyclovir hydrochloride , convert acyclovir body , increase acyclovir bioavailability 3-5 fold .</brief_summary>
	<brief_title>The Safety Effectiveness Valacyclovir HCl Treatment Herpes Simplex Varicella/Zoster Infections HIV-1 Infected Children</brief_title>
	<detailed_description>Varicella zoster common problem HIV-infected child . It believe chronic oral therapy acyclovir may result subtherapeutic concentration acyclovir , result resistance drug . Valacyclovir hydrochloride , convert acyclovir body , increase acyclovir bioavailability 3-5 fold . In first cohort , patient stable herpes simplex virus receive valacyclovir hydrochloride 1 2 dos , depend body surface area ( BSA ) , 10 day . If acceptable safety see dose level , second cohort patient stable herpes simplex virus receive high dose , depend BSA , 10 day . A third cohort patient varicella zoster receive select dose base result previous cohort .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Antiretrovirals . PCP prophylaxis . IVIG , GCSF , erythropoietin . Concurrent Treatment : Allowed : Transfusions . Patients must : Localized mucocutaneous herpes simplex OR undisseminated varicella zoster . HIV positive . NOTE : Varicella patient must NOT AIDS . CD4 count &gt; = 100 cells/mm3 ( herpes simplex zoster patient ) OR &gt; = 250 cells/mm3 ( varicella patient ) . BSA &gt; 0.6 m2 . Ability swallow solid dosage formulation . Prior Medication : Allowed : Prior VZV immune globulin and/or IVIG . Antiretrovirals stable dose least 14 day . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Clinical evidence pneumonitis . Severe abdominal pain back pain . Encephalopathy . Hemorrhagic varicella . Zoster involve ophthalmic branch trigeminal nerve . Severe gastrointestinal disorder . Concurrent Medication : Excluded : Agents potential activity HSV VZV , acyclovir , famciclovir , ganciclovir , foscarnet , sorivudine . Probenecid . Aspartamine within 48 hour prior pharmacokinetic sampling . Patients follow prior condition exclude : Grade 2 creatinine value within past 30 day . Grade 3 hematologic hepatic value within past 30 day . Prior hypersensitivity and/or allergic reaction acyclovir . Grade 3 4 mental status change within past 30 day . Prior Medication : Excluded : Acyclovir within 1 week prior study entry . Steroids within 4 week prior onset varicella lesion .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Herpes Zoster</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Herpes Simplex</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>valacyclovir</keyword>
	<keyword>Chickenpox</keyword>
</DOC>